Together4RD position statement on collaboration between European reference networks and industry.

ERNs European reference network Networking Public–private-partnership Rare disease Rare diseases Research

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
05 09 2023
Historique:
received: 11 04 2023
accepted: 08 08 2023
medline: 7 9 2023
pubmed: 6 9 2023
entrez: 5 9 2023
Statut: epublish

Résumé

Notwithstanding two decades of policy and legislation in Europe, aimed to foster research and development in rare conditions, only 5-6% of rare diseases have dedicated treatments. Given with the huge number of conditions classed as rare (which is increasing all the time), this equates to major unmet need for patients (over 30 million in the EU alone). Worryingly, the pace of Research and Innovation in Europe is lagging behind other regions of the world, and a seismic shift in the way in which research is planned and delivered is required, in order to remain competitive and-most importantly-bring meaningful, disease-altering treatments to those who desperately need them. The European Reference Networks (ERNs), launched in 2017, hold major potential to alleviate many of these challenges, and more, but only if adequately supported (financially, technically, and via robust policies and infrastructure) to realise that potential: and even then, only if able to forge robust collaborations harnessing the expertise, resources, knowledge and data of all stakeholders involved in rare disease, including Industry. To-date, however, ERN-Industry interactions have been largely limited, for a range of reasons (concerning barriers both tangible and perceived). This Position Statement analyses these barriers, and explains how Together4RD is seeking to move the needle here, by learning from case studies, exploring frameworks for collaboration, and launching pilots to explore how best to plan and deliver multistakeholder interactions addressing real research needs.

Identifiants

pubmed: 37670358
doi: 10.1186/s13023-023-02853-9
pii: 10.1186/s13023-023-02853-9
pmc: PMC10478454
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

272

Investigateurs

Alexis Arzimanoglou (A)
Hélène Dollfus (H)
Dorothée Leroux (D)
Maurizio Scarpa (M)
Franz Schaefer (F)
Alain Verloes (A)
Matt Bolz-Johnson (M)
None Daria Julkowska
Ana Rath (A)
Victoria Hedley (V)
Anton Ussi (A)
Yanis Mimouni (Y)
Rima Nabbout (R)
Morgane Cuisenier (M)
Anne-Sophie Chalandon (AS)
Toon Digneffe (T)
Gabriella Almberg (G)
Matteo Scarabelli (M)
Leander Vranken (L)

Informations de copyright

© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).

Références

JMIR Med Inform. 2022 May 20;10(5):e32158
pubmed: 35594066
Yale J Biol Med. 2021 Dec 29;94(4):687-692
pubmed: 34970107
J Community Genet. 2021 Apr;12(2):205-206
pubmed: 33945116
Eur J Hum Genet. 2020 Feb;28(2):165-173
pubmed: 31527858
Front Endocrinol (Lausanne). 2022 Mar 04;13:832063
pubmed: 35317224
Orphanet J Rare Dis. 2019 Jul 12;14(1):175
pubmed: 31300010
J Community Genet. 2021 Apr;12(2):217-229
pubmed: 33733400
Endocrine. 2021 Mar;71(3):549-554
pubmed: 33528763
Ann Ist Super Sanita. 2019 Jul-Sep;55(3):296-304
pubmed: 31553326
J Community Genet. 2021 Apr;12(2):241-246
pubmed: 33884523
PLoS Curr. 2013 Jan 10;5:
pubmed: 23330068
Genet Med. 2020 Jan;22(1):219-226
pubmed: 31337884
Orphanet J Rare Dis. 2017 Aug 7;12(1):137
pubmed: 28784158
N Engl J Med. 2017 May 4;376(18):1762-1769
pubmed: 28467868
J Biomed Semantics. 2022 Mar 15;13(1):9
pubmed: 35292119
Eur J Hum Genet. 2016 Aug;24(9):1248-54
pubmed: 26860059
Orphanet J Rare Dis. 2016 Feb 24;11:17
pubmed: 26911987

Auteurs

Victoria Hedley (V)

Newcastle University, Newcastle Upon Tyne, UK. vjhedley@hotmail.co.uk.

Matt Bolz-Johnson (M)

EURORDIS (Rare Diseases Europe), Paris, France.

Ines Hernando (I)

EURORDIS (Rare Diseases Europe), Paris, France.

Rosalind Kenward (R)

FIPRA International, Brussels, Belgium.

Rima Nabbout (R)

Pediatric Neurology Department, Hôpital Necker Enfants Malades, APHP, Universite Paris Cité, Institut Imagine, Paris, France.

Clara Romero (C)

FIPRA International, Brussels, Belgium.

Franz Schaefer (F)

Center For Pediatrics and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany.

Sheela Upadhyaya (S)

FIPRA International, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH